Pulling SEC filings + quote and writing the call…

Jade Biosciences, Inc.
Next earnings Aug 11, 2026 (before open) · consensus $-0.66 EPS
Last earnings -3.6% on 2026-05-07
Conservative balance sheet (liabilities/equity 0.05x).
Jade Biosciences, Inc. shows limited reported revenue, and -38.3% ROE.
Sources: SEC EDGAR (CIK 0001798749, latest 10-Q filed 2026-05-07) · EODHD · as of 6/25/2026, 10:18:39 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.0M | -$53.2M | -$81.4M | -$74.6M | -$114M |
| Net income | -$23.0M | -$51.5M | -$75.5M | -$69.6M | -$127M |
| Diluted EPS | -$1.87 | -$2.10 | -$2.87 | -$2.44 | -$3.19 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1075 tracked peers · median
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-02-12 | Dahms Bradford D. Chief Financial Officer | Award | 37.8K | |
| 2026-02-12 | Balta Elizabeth See Remarks | Award | 28.1K | |
| 2026-02-12 | Frohlich Tom Chief Executive Officer | Award | 78.8K |